Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NASDAQ:SERA

Sera Prognostics Q2 2026 Earnings Report

Sera Prognostics logo
$1.93 -0.17 (-8.10%)
Closing price 08/4/2026 04:00 PM Eastern
Extended Trading
$1.94 +0.01 (+0.52%)
As of 08/4/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Sera Prognostics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.14
Beat/Miss
N/A
One Year Ago EPS
N/A

Sera Prognostics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.07 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sera Prognostics Announcement Details

Quarter
Q2 2026
Date
8/12/2026
Time
After Market Closes
Conference Call Date
Wednesday, August 12, 2026
Conference Call Time
5:00PM ET

Conference Call Resources

Sera Prognostics Earnings Headlines

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026
July 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal-year-2026-financial-results-on-august-12-2026-302837088.html
PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
July 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/prime-subgroup-analysis-demonstrates-22-reduction-in-nicu-admissions-in-first-time-pregnancies-using-pretrm-test-guided-care-302822056.html
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
June 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/sera-prognostics-announces-appointment-of-mark-capone-to-its-board-of-directors-302814637.html
SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH
June 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/sera-prognostics-collaborates-on-arpa-h-award-to-advance-point-of-care-diagnostic-for-safer-birth-302809587.html
SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY
June 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/sera-applauds-illinois-initiative-to-expand-medicaid-coverage-for-proteomic-blood-testing-in-pregnancy-302808266.html
See More Sera Prognostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sera Prognostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sera Prognostics and other key companies, straight to your email.

About Sera Prognostics

Sera Prognostics (NASDAQ:SERA) is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test. The company has secured relevant regulatory clearances and reimbursement pathways, and continues to explore additional clinical applications for its proteomic platform. Collaborative efforts with academic institutions and health systems support ongoing studies aimed at demonstrating the test’s utility in diverse patient populations.

Headquartered in Salt Lake City, Utah, Sera Prognostics is led by President and Chief Executive Officer Zachary Carr, who brings experience in commercializing diagnostic technologies. Under his leadership, the company has built a multidisciplinary team of professionals in molecular diagnostics, clinical operations, regulatory affairs, and market access. Sera Prognostics remains dedicated to advancing maternal–fetal health and expanding its footprint through partnerships with healthcare organizations and research sponsors.

View Sera Prognostics Profile
Earnings Tools